Literature DB >> 11931417

Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains.

M Uzun1, Z Erturan, O Anğ.   

Abstract

In order to indicate the cross-resistance between rifampin (RMP) and rifabutin (RBU), minimal inhibitory concentrations (MICs) of RBU were investigated in 50 Mycobacterium tuberculosis strains. The MIC values of 25 RMP-susceptible (to 2 microg/ml) and 25 RMP-resistant (to 2 microg/ml) M. tuberculosis strains against RBU were determined by the Bactec TB 460 system. All of the RMP-susceptible strains were also susceptible to RBU (MIC < or = 1 microg/ml). Three out of 25 (12%) RMP-resistant strains were determined as susceptible to RBU. The high level cross-resistance (88%) obtained in this study highlights the importance of testing susceptibility to RBU prior to its inclusion in the tuberculosis treatment regimens at the Istanbul Faculty of Medicine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931417

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis.

Authors:  Huang-Yao Chen; Ming-Chih Yu; Wei-Lun Huang; Mei-Hua Wu; Yung-Lin Chang; Chien-Rai Che; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

2.  Rapid determination of rifampin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR.

Authors:  Tanil Kocagoz; Zeynep Saribas; Alpaslan Alp
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

Authors:  Michael G Whitfield; Robin M Warren; Vanessa Mathys; Lesley Scott; Elise De Vos; Wendy Stevens; Elizabeth M Streicher; Guido Groenen; Frederick A Sirgel; Annelies Van Rie
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

4.  Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.

Authors:  Maha R Farhat; Jaimie Sixsmith; Roger Calderon; Nathan D Hicks; Sarah M Fortune; Megan Murray
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

5.  Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.

Authors:  Zenda L Berrada; Shou-Yean Grace Lin; Timothy C Rodwell; Duylinh Nguyen; Gisela F Schecter; Lucy Pham; J Michael Janda; Wael Elmaraachli; Antonino Catanzaro; Edward Desmond
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-03       Impact factor: 2.803

6.  Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

Authors:  W ElMaraachli; M Slater; Z L Berrada; S-Y G Lin; A Catanzaro; E Desmond; C Rodrigues; T C Victor; V Crudu; M T Gler; T C Rodwell
Journal:  Int J Tuberc Lung Dis       Date:  2015-10       Impact factor: 2.373

7.  Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.

Authors:  Sandeep Sharma; Noton K Dutta
Journal:  Front Microbiol       Date:  2017-11-27       Impact factor: 5.640

8.  Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.

Authors:  Wei Jing; Yu Pang; Zhaojing Zong; Jing Wang; Ru Guo; Fengmin Huo; Guanglu Jiang; Yifeng Ma; Hairong Huang; Naihui Chu
Journal:  Front Microbiol       Date:  2017-09-14       Impact factor: 5.640

Review 9.  Medical treatment of pulmonary multidrug-resistant tuberculosis.

Authors:  Tae Sun Shim; Kyung-Wook Jo
Journal:  Infect Chemother       Date:  2013-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.